Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring

BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failur...

Descripción completa

Detalles Bibliográficos
Autores principales: von Wyl, Viktor, Cambiano, Valentina, Jordan, Michael R., Bertagnolio, Silvia, Miners, Alec, Pillay, Deenan, Lundgren, Jens, Phillips, Andrew N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414499/
https://www.ncbi.nlm.nih.gov/pubmed/22905175
http://dx.doi.org/10.1371/journal.pone.0042834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414499/
https://www.ncbi.nlm.nih.gov/pubmed/22905175
http://dx.doi.org/10.1371/journal.pone.0042834

Ejemplares similares